Glory Health Industry (2329) Fundamentals 2026 — Revenue Analysis | SniperIQ
Glory Health Industry (2329) is a CN-listed Real Estate company in Real Estate - Development with a market capitalization of HK
Glory Health Industry (2329) has a market capitalization of approximately HK
Glory Health Industry's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.0x. Valuation multiples are best compared with Real Estate sector peers rather than read in isolation.
Glory Health Industry runs a net profit margin of -176.0%, a gross margin of -29.7%, and an operating margin of -74.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Glory Health Industry reported revenue of ¥1.0B for fiscal year 2025, with net income of -¥1.8B and earnings per share (EPS) of -0.41. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Glory Health Industry does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Glory Health Industry carries a debt-to-equity ratio of 2.94x and a current ratio of 0.68x, with a market beta of 0.36. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Glory Health Industry (2329) the key facts are: market cap HK
Get Glory Health Industry's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.